These results are consistent with that of a study from the Israeli Lung Cancer Group suggesting favorable outcomes with ICI in a smaller population of patients with BRAF-mutant NSCLC with either V600 or non-V600 alterations, as well as with an analysis of BRAF-mutant patients enrolled in the Italian Expanded Access Program of second-line nivolumab [57,58]. This evidence concerns the gene BRAF and lung cancer.